KEMASKINI Hematologi / Onkologi 2024
Kongres ESMO 2023
Datopotamab deruxtecan achieved the PFS endpoint for previously treated NSCLC. 177Lu PSMA-617 increases rPFS for metastatic castration resistant prostate cancer that is taxane-naive. Amivantamab combinations therapies are emerging as new options for EGFR mutated advanced NSCLC. Antibody-drug combinations improve outcomes for patients who have metastatic or inoperable breast cancer. Digital health technologies are revolutionising cancer care.
Anda menggunakan versi lama pelayar web anda, jadi sesetengah ciri mungkin tidak dipaparkan dengan betul.
Keperluan MINIMAL: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15-18, Apple Safari 7, SeaMonkey 2.15-2.23.
Meeting Resources19 Oct 2023OncologyPRO now offers meeting resources: +3.000 slides and webcasts; abstracts and ePosters.Access to resources.
OncologyPRO kini menawarkan sumber mesyuarat: +3.000 slaid dan siaran web; abstrak dan ePoster.
Daily ReporterDatopotamab deruxtecan reached the PFS endpoint for previously treated NSCLC23 Oct 2023TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
TROP2-directed ADC increased PFS and reduced toxicity in comparison with chemotherapy, but the results of TROPION Lung01 are not practice changing.
Daily Reporter177Lu PSMA-617 menambah baik rPFS untuk pesakit kanser prostat tahan kastrasi metastatik yang naif cukai23 Okt 2023Penemuan percubaan PSMAsebelum ini dihadkan oleh fakta bahawa mereka tidak menunjukkan manfaat dari segi OS.
Daftar untuk tiket atau gerai
Peta Tempat dan Hotel Sekitar
Munich - Holiday Inn Munich - Pusat Bandar, Bavaria, Jerman Munich - Holiday Inn Munich - Pusat Bandar, Bavaria, Jerman
Langgan